{"id":"https://openalex.org/W1971554504","doi":"https://doi.org/10.1158/1078-0432.ccr-12-3080","title":"Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control","display_name":"Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control","alternate_titles":[],"publication_year":2013,"publication_date":"2013-04-15","ids":{"openalex":"https://openalex.org/W1971554504","doi":"https://doi.org/10.1158/1078-0432.ccr-12-3080","mag":"1971554504","pmid":"https://pubmed.ncbi.nlm.nih.gov/23444228"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-12-3080","doi":"https://doi.org/10.1158/1078-0432.ccr-12-3080","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-3080","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1971554504"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100713900","display_name":"Caroline Robert","orcid":"https://orcid.org/0000-0002-9493-0238","observed_orcids":["https://orcid.org/0000-0002-9493-0238"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE","FR","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Caroline Robert","raw_affiliation_strings":["Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4210100502","https://openalex.org/I4210117453","https://openalex.org/I4210119759"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034365278","display_name":"Dirk Schadendorf","orcid":"https://orcid.org/0000-0003-3524-7858","observed_orcids":["https://orcid.org/0000-0003-3524-7858"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE","FR","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dirk Schadendorf","raw_affiliation_strings":["Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4210100502","https://openalex.org/I4210117453","https://openalex.org/I4210119759"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046712639","display_name":"MARIANNE E. MESSINA","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE","FR","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marianne Messina","raw_affiliation_strings":["Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4210100502","https://openalex.org/I4210117453","https://openalex.org/I4210119759"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084967339","display_name":"Frank Stephen Hodi","orcid":"https://orcid.org/0000-0001-6825-091X","observed_orcids":["https://orcid.org/0000-0001-6825-091X"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE","FR","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"F. Stephen Hodi","raw_affiliation_strings":["Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4210100502","https://openalex.org/I4210117453","https://openalex.org/I4210119759"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060495866","display_name":"Steven J O'Day","orcid":"https://orcid.org/0009-0005-5345-5417","observed_orcids":["https://orcid.org/0009-0005-5345-5417"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4210100502","display_name":"Beverly Hills Cancer Center","ror":"https://ror.org/00j1j3213","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210100502"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE","FR","US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steven O'Day","raw_affiliation_strings":["Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Authors' Affiliations:\u20081Institut Gustave Roussy, Villejuif, France; 2University Hospital Essen, Essen, Germany; 3Bristol-Myers Squibb, Wallingford, Connecticut; 4Dana-Farber Cancer Institute, Boston, Massachusetts; and 5The Beverly Hills Cancer Center, Beverly Hills, California","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4210100502","https://openalex.org/I4210117453","https://openalex.org/I4210119759"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":10.2296,"has_fulltext":false,"cited_by_count":163,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99009449,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":96,"max":100},"biblio":{"volume":"19","issue":"8","first_page":"2232","last_page":"2239"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.975600004196167,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.975600004196167,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.020600000396370888,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0010000000474974513,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ipilimumab","display_name":"ipilimumab","score":1.0},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8889999985694885},{"id":"https://openalex.org/keywords/retreatment","display_name":"retreatment","score":0.8560000061988831},{"id":"https://openalex.org/keywords/ctla-4-blockade","display_name":"CTLA-4 blockade","score":0.9039999842643738},{"id":"https://openalex.org/keywords/disease-progression","display_name":"disease progression","score":0.7400000095367432},{"id":"https://openalex.org/keywords/best-overall-response","display_name":"best overall response","score":0.9120000004768372},{"id":"https://openalex.org/keywords/disease-control-rate","display_name":"disease control rate","score":0.9779999852180481},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.6660000085830688}],"concepts":[{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.9799773693084717},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9199749231338501},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.7297979593276978},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6795185804367065},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5922431349754333},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.521987795829773},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4856247007846832},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.44844985008239746},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3865816295146942},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3653067648410797},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3486576974391937},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.32315418124198914},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.07074305415153503},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.0},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000074324","descriptor_name":"Ipilimumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005767","descriptor_name":"Gastrointestinal Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000628","qualifier_name":"therapy","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012871","descriptor_name":"Skin Diseases","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019496","descriptor_name":"Cancer Vaccines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019496","descriptor_name":"Cancer Vaccines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D060908","descriptor_name":"CTLA-4 Antigen","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.ccr-12-3080","doi":"https://doi.org/10.1158/1078-0432.ccr-12-3080","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-12-3080","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:23444228","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23444228","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:bibliographie.ub.uni-due.de:ubo_mods_00088569","doi":null,"is_oa":false,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pubmed/23444228","pdf_url":null,"source":{"id":"https://openalex.org/S7407055102","display_name":"Universit\u00e4tsbibliographie, Universit\u00e4t Duisburg-Essen","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":30,"referenced_works":["https://openalex.org/W1529517822","https://openalex.org/W1733656319","https://openalex.org/W1979446115","https://openalex.org/W1982889687","https://openalex.org/W2018695684","https://openalex.org/W2020727013","https://openalex.org/W2036539860","https://openalex.org/W2040851929","https://openalex.org/W2049127230","https://openalex.org/W2060813234","https://openalex.org/W2081521066","https://openalex.org/W2094549539","https://openalex.org/W2094569028","https://openalex.org/W2095826876","https://openalex.org/W2096151993","https://openalex.org/W2097995306","https://openalex.org/W2100158834","https://openalex.org/W2105459360","https://openalex.org/W2112069616","https://openalex.org/W2119198740","https://openalex.org/W2121626779","https://openalex.org/W2122942163","https://openalex.org/W2123363005","https://openalex.org/W2126882378","https://openalex.org/W2144304036","https://openalex.org/W2145592659","https://openalex.org/W2148576689","https://openalex.org/W2155189639","https://openalex.org/W2164918836","https://openalex.org/W2168334855"],"related_works":["https://openalex.org/W2059928795","https://openalex.org/W2156261087","https://openalex.org/W3029920221","https://openalex.org/W2596109747","https://openalex.org/W2042576421","https://openalex.org/W2511241336","https://openalex.org/W2246004191","https://openalex.org/W2054535181","https://openalex.org/W2140521678","https://openalex.org/W2088542183"],"abstract_inverted_index":{"PURPOSE:":[0],"Ipilimumab":[1,199],"is":[2],"a":[3,27,116,135,217],"fully":[4],"human":[5],"monoclonal":[6],"antibody":[7],"against":[8],"cytotoxic":[9],"T-lymphocyte-associated":[10],"antigen-4":[11],"(CTLA-4)":[12],"that":[13,222],"has":[14],"been":[15],"shown":[16],"to":[17,39,75,93,221],"improve":[18],"survival":[19],"in":[20,26,33,156,207],"patients":[21,32,58,89,139,155,209],"with":[22,49,73,95,216],"pretreated,":[23],"advanced":[24],"melanoma":[25],"phase":[28,84],"III":[29,85],"trial.":[30],"Some":[31],"this":[34],"study":[35,78],"who":[36,210],"initially":[37],"responded":[38],"ipilimumab":[40,96,102,158,162],"treatment":[41,94,126,227],"but":[42],"later":[43],"progressed":[44],"were":[45,90,140,166,181,196],"eligible":[46],"for":[47,56,132,152],"retreatment":[48,192,212],"their":[50,225],"original":[51,226],"randomized":[52],"regimen.":[53,228],"Here,":[54],"outcomes":[55],"these":[57,112],"concerning":[59],"baseline":[60],"characteristics,":[61],"best":[62],"overall":[63,77,144],"response,":[64],"and":[65,71,127,161,171,177,183,193],"disease":[66,124,178,206,214],"control":[67,179],"rate":[68],"are":[69],"assessed":[70],"considered":[72],"respect":[74],"the":[76,83,129,157],"population.":[79],"EXPERIMENTAL":[80],"DESIGN:":[81],"In":[82],"study,":[86],"676":[87],"pretreated":[88],"randomly":[91],"allocated":[92],"3":[97,103,167,172],"mg/kg":[98,104],"plus":[99,105,149,159,163],"gp100":[100,108,160],"vaccine,":[101],"placebo,":[106],"or":[107,118,122],"vaccine":[109],"alone.":[110],"Of":[111],"patients,":[113],"32":[114],"had":[115],"partial":[117,150],"complete":[119],"objective":[120,202],"response":[121,145],"stable":[123,205],"after":[125],"met":[128],"eligibility":[130],"criteria":[131],"retreatment,":[133],"although":[134],"total":[136],"of":[137,168,173,188],"40":[138],"retreated.":[141],"RESULTS:":[142],"Best":[143],"rates":[146,180],"(complete":[147],"responses":[148,203],"responses)":[151],"31":[153],"retreatment-eligible":[154],"placebo":[164],"groups":[165],"23":[169],"(13.0%)":[170],"8":[174],"(37.5%),":[175],"respectively,":[176],"65.2%":[182],"75.0%.":[184],"No":[185],"new":[186],"types":[187],"toxicities":[189],"occurred":[190],"during":[191,224],"most":[194],"events":[195],"mild-to-moderate.":[197],"CONCLUSION:":[198],"provided":[200],"durable":[201],"and/or":[204],"qualifying":[208],"received":[211],"upon":[213],"progression":[215],"similar":[218],"toxicity":[219],"profile":[220],"seen":[223]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1971554504","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":20},{"year":2019,"cited_by_count":14},{"year":2018,"cited_by_count":9},{"year":2017,"cited_by_count":16},{"year":2016,"cited_by_count":14},{"year":2015,"cited_by_count":20},{"year":2014,"cited_by_count":24},{"year":2013,"cited_by_count":11}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
